{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:25Z","timestamp":1792931845749,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06919-z","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:34:46Z","timestamp":1774946086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy"],"prefix":"10.1007","volume":"105","author":[{"given":"Mutaz Jamal","family":"Al-khreisat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-5783","authenticated-orcid":false,"given":"Waleed K.","family":"Abdulsahib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsan Khudhair","family":"Jasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Malathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeepta Sekhar","family":"Patro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Alex","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashna","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilnoz","family":"Buriyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"2","key":"6919_CR1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12032-023-02280-7","volume":"41","author":"NR Raghani","year":"2024","unstructured":"Raghani NR, Chorawala MR, Mahadik M, Patel RB, Prajapati BG, Parekh PS (2024) Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies. Med Oncol 41(2):51","journal-title":"Med Oncol"},{"issue":"21","key":"6919_CR2","doi-asserted-by":"crossref","first-page":"11384","DOI":"10.3390\/ijms252111384","volume":"25","author":"R Masnikosa","year":"2024","unstructured":"Masnikosa R, Cvetkovi\u0107 Z, Piri\u0107 D (2024) Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review. Int J Mol Sci 25(21):11384","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6919_CR3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z et al (2024) Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther 9(1):170","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"6919_CR4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.21037\/atm-20-6833","volume":"9","author":"H Hatic","year":"2021","unstructured":"Hatic H, Sampat D, Goyal G (2021) Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Ann Transl Med 9(12):1037","journal-title":"Ann Transl Med"},{"issue":"1","key":"6919_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gendis.2019.12.004","volume":"8","author":"X Jiang","year":"2021","unstructured":"Jiang X, Liu G, Li Y, Pan Y (2021) Immune checkpoint: The novel target for antitumor therapy. Genes Dis 8(1):25\u201337","journal-title":"Genes Dis"},{"key":"6919_CR6","doi-asserted-by":"crossref","first-page":"1323914","DOI":"10.3389\/fonc.2024.1323914","volume":"14","author":"P Pophali","year":"2024","unstructured":"Pophali P, Varela JC, Rosenblatt J (2024) Immune checkpoint blockade in hematological malignancies: current state and future potential. Front Oncol 14:1323914","journal-title":"Front Oncol"},{"issue":"3","key":"6919_CR7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1515\/oncologie-2024-0037","volume":"26","author":"H Guo","year":"2024","unstructured":"Guo H, Hou Y, Wang C, Ding J (2024) How to optimize the immune checkpoint blockade therapy for cancers? Oncologie 26(3):343\u2013348","journal-title":"Oncologie"},{"issue":"17","key":"6919_CR8","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 33(17):1974\u20131982","journal-title":"J Clin Oncol"},{"issue":"4","key":"6919_CR9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.gendis.2022.07.024","volume":"10","author":"S Kumar","year":"2023","unstructured":"Kumar S, Chatterjee M, Ghosh P, Ganguly KK, Basu M, Ghosh MK (2023) Targeting PD-1\/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes Dis 10(4):1318\u20131350","journal-title":"Genes Dis"},{"key":"6919_CR10","doi-asserted-by":"crossref","first-page":"1288172","DOI":"10.3389\/fonc.2023.1288172","volume":"13","author":"A Tsumura","year":"2023","unstructured":"Tsumura A, Levis D, Tuscano JM (2023) Checkpoint inhibition in hematologic malignancies. Front Oncol 13:1288172","journal-title":"Front Oncol"},{"issue":"1","key":"6919_CR11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y (2023) Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol 16(1):101","journal-title":"J Hematol Oncol"},{"issue":"14","key":"6919_CR12","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.3390\/cancers17142292","volume":"17","author":"MN Alibrahim","year":"2025","unstructured":"Alibrahim MN, Carbone A, Alsaleh N, Gloghini A (2025) Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies. Cancers 17(14):2292","journal-title":"Cancers"},{"issue":"1","key":"6919_CR13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.17793","volume":"196","author":"E Gerhard-Hartmann","year":"2022","unstructured":"Gerhard-Hartmann E, Goergen H, Br\u00f6ckelmann PJ, Mottok A, Steinm\u00fcller T, Grund J et al (2022) 9p24. 1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. Br J Haematol 196(1):116\u2013126","journal-title":"Br J Haematol"},{"key":"6919_CR14","doi-asserted-by":"crossref","first-page":"1420920","DOI":"10.3389\/fonc.2024.1420920","volume":"14","author":"D Ribatti","year":"2024","unstructured":"Ribatti D, Cazzato G, Tamma R, Annese T, Ingravallo G, Specchia G (2024) Immune checkpoint inhibitors targeting PD-1\/PD-L1 in the treatment of human lymphomas. Front Oncol 14:1420920","journal-title":"Front Oncol"},{"issue":"4","key":"6919_CR15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","volume":"59","author":"P Boddu","year":"2018","unstructured":"Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N (2018) The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59(4):790\u2013802","journal-title":"Leuk Lymphoma"},{"key":"6919_CR16","doi-asserted-by":"publisher","unstructured":"J\u00e4dersten M, Lilienthal I, Nilsson C, Fredrikson L, Pronk CJ, Juul-Dam KL, Kontro M, Herold N (2025) Precision oncology to overcome resistance in R\/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments. J Intern Med 298(4):297\u2013318. https:\/\/doi.org\/10.1111\/joim.70004","DOI":"10.1111\/joim.70004"},{"issue":"19","key":"6919_CR17","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.3390\/cancers14194941","volume":"14","author":"G Cassanello","year":"2022","unstructured":"Cassanello G, Pasquale R, Barcellini W, Fattizzo B (2022) Novel therapies for unmet clinical needs in myelodysplastic syndromes. Cancers 14(19):4941","journal-title":"Cancers"},{"issue":"3","key":"6919_CR18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"MZ Wojtukiewicz","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K, G\u00f3rska M, Polity\u0144ska B, Wojtukiewicz AM et al (2021) Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev 40(3):949\u2013982","journal-title":"Cancer Metastasis Rev"},{"key":"6919_CR19","volume-title":"Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma","author":"J Huang","year":"2022","unstructured":"Huang J, Huang J (2022) Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. IntechOpen, Immune Checkpoint Inhibitors-New Insights and Recent Progress"},{"issue":"10","key":"6919_CR20","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3390\/cancers15102718","volume":"15","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, Theocharopoulos C, Lialios P-P, Foteinou D, Koumprentziotis I-A, Xynos G et al (2023) Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers 15(10):2718","journal-title":"Cancers"},{"issue":"19","key":"6919_CR21","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.3390\/ijms241915019","volume":"24","author":"C Liberatore","year":"2023","unstructured":"Liberatore C, Di Ianni M (2023) Novel approaches to treatment of acute myeloid leukemia relapse post allogeneic stem cell transplantation. Int J Mol Sci 24(19):15019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6919_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","volume":"24","author":"TS Nowicki","year":"2018","unstructured":"Nowicki TS, Hu-Lieskovan S, Ribas A (2018) Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J 24(1):47\u201353","journal-title":"Cancer J"},{"key":"6919_CR23","doi-asserted-by":"publisher","unstructured":"Yolcu A, Aladag Karakulak E, Goker H (2025) Therapeutic options for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation. Expert Rev Hematol. https:\/\/doi.org\/10.1080\/17474086.2025.2547866Yolcu","DOI":"10.1080\/17474086.2025.2547866Yolcu"},{"issue":"5","key":"6919_CR24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y (2019) PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother 15(5):1111\u20131122","journal-title":"Hum Vaccin Immunother"},{"key":"6919_CR25","doi-asserted-by":"publisher","unstructured":"Kim TK, Han X, Hu Q, Vandsemb EN, Fielder CM, Hong J, Zheng S, Geller RB, Beury DW, Tan L, Chen M, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Davies FE, Barlogie B, Gupta SK, Wang H, Chen L, Madad LA, Walker CJ (2024) PD-1H\/VISTA mediates immune evasion in acute myeloid leukemia. J Clin Invest 134(3):e161695. https:\/\/doi.org\/10.1172\/JCI161695","DOI":"10.1172\/JCI161695"},{"key":"6919_CR26","doi-asserted-by":"publisher","unstructured":"Alturki NA (2023) Review of the immune checkpoint inhibitors in the context of cancer treatment. J Clin Med 12(13):4301. https:\/\/doi.org\/10.3390\/jcm12134301","DOI":"10.3390\/jcm12134301"},{"issue":"21","key":"6919_CR27","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.3390\/cancers13215367","volume":"13","author":"K Singh","year":"2021","unstructured":"Singh K, Hotchkiss KM, Patel KK, Wilkinson DS, Mohan AA, Cook SL et al (2021) Enhancing T cell chemotaxis and infiltration in glioblastoma. Cancers 13(21):5367","journal-title":"Cancers"},{"key":"6919_CR28","doi-asserted-by":"crossref","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ (2022) Managing the TME to improve the efficacy of cancer therapy. Front Immunol 13:954992","journal-title":"Front Immunol"},{"issue":"8","key":"6919_CR29","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY et al (2022) Association of high tumor mutation burden in non\u2013small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol 8(8):1160\u20131168","journal-title":"JAMA Oncol"},{"key":"6919_CR30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol 8:86","journal-title":"Front Oncol"},{"key":"6919_CR31","doi-asserted-by":"crossref","first-page":"100079","DOI":"10.1016\/j.iotech.2022.100079","volume":"14","author":"L Chocarro","year":"2022","unstructured":"Chocarro L, Blanco E, Arasanz H, Fern\u00e1ndez-Rubio L, Bocanegra A, Echaide M et al (2022) Clinical landscape of LAG-3-targeted therapy. Immunooncol Technol 14:100079","journal-title":"Immunooncol Technol"},{"issue":"23","key":"6919_CR32","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","volume":"28","author":"LP Andrews","year":"2022","unstructured":"Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA (2022) Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res 28(23):5030\u20135039","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6919_CR33","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10(3):727\u2013742","journal-title":"Am J Cancer Res"},{"key":"6919_CR34","doi-asserted-by":"crossref","unstructured":"Qiu X, Yu Z, Lu X, Jin X, Zhu J, Zhang R (2024) PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer. China Anti-Cancer Association, pp 970\u2013976","DOI":"10.20892\/j.issn.2095-3941.2024.0436"},{"issue":"5","key":"6919_CR35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14737140.2021.1865814","volume":"21","author":"AM Zeidan","year":"2021","unstructured":"Zeidan AM, Komrokji RS, Brunner AM (2021) TIM-3 pathway dysregulation and targeting in cancer. Expert Rev Anticancer Ther 21(5):523\u2013534","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"6919_CR36","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00277-025-06304-2","volume":"104","author":"F Meng","year":"2025","unstructured":"Meng F, Xiang M, Liu Y, Zeng D (2025) TIGIT\/PVR axis regulates anti-tumor immunity in hematologic malignancies. Ann Hematol 104(3):1415\u20131426","journal-title":"Ann Hematol"},{"issue":"23","key":"6919_CR37","doi-asserted-by":"crossref","first-page":"14885","DOI":"10.3390\/ijms232314885","volume":"23","author":"S Pagliuca","year":"2022","unstructured":"Pagliuca S, Gurnari C, Zhang K, Kewan T, Bahaj W, Mori M et al (2022) Comprehensive transcriptomic analysis of VISTA in acute myeloid leukemia: insights into its prognostic value. Int J Mol Sci 23(23):14885","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6919_CR38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40364-024-00556-2","volume":"12","author":"A Andrzejczak","year":"2024","unstructured":"Andrzejczak A, Karabon L (2024) BTLA biology in cancer: from bench discoveries to clinical potentials. Biomark Res 12(1):8","journal-title":"Biomark Res"},{"issue":"1","key":"6919_CR39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J et al (2020) Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther 5(1):8","journal-title":"Signal Transduct Target Ther"},{"key":"6919_CR40","doi-asserted-by":"crossref","first-page":"100070","DOI":"10.1016\/j.iotech.2022.100070","volume":"13","author":"R Maute","year":"2022","unstructured":"Maute R, Xu J, Weissman IL (2022) CD47-SIRP\u03b1-targeted therapeutics: status and prospects. Immunooncol Technol 13:100070","journal-title":"Immunooncol Technol"},{"issue":"1","key":"6919_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-021-03815-z","volume":"148","author":"YC Chen","year":"2022","unstructured":"Chen YC, Shi W, Shi JJ, Lu JJ (2022) Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective. J Cancer Res Clin Oncol 148(1):1\u201314","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"6919_CR42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-024-01019-5","volume":"14","author":"A Ray","year":"2024","unstructured":"Ray A, Du T, Wan X, Song Y, Pillai SC, Musa MA et al (2024) A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death. Blood Cancer J 14(1):58","journal-title":"Blood Cancer J"},{"key":"6919_CR43","doi-asserted-by":"crossref","first-page":"1110325","DOI":"10.3389\/fimmu.2023.1110325","volume":"14","author":"X Jiang","year":"2023","unstructured":"Jiang X, Wu X, Xiao Y, Wang P, Zheng J, Wu X et al (2023) The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy. Front Immunol 14:1110325","journal-title":"Front Immunol"},{"issue":"11","key":"6919_CR44","doi-asserted-by":"crossref","first-page":"e1217374","DOI":"10.1080\/2162402X.2016.1217374","volume":"5","author":"D Atanackovic","year":"2016","unstructured":"Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T (2016) Immunotherapies targeting CD38 in Multiple Myeloma. Oncoimmunology 5(11):e1217374","journal-title":"Oncoimmunology"},{"issue":"11","key":"6919_CR45","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/13543784.2020.1814253","volume":"29","author":"Y Jiao","year":"2020","unstructured":"Jiao Y, Yi M, Xu L, Chu Q, Yan Y, Luo S et al (2020) CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. Expert Opin Investig Drugs 29(11):1295\u20131308","journal-title":"Expert Opin Investig Drugs"},{"key":"6919_CR46","doi-asserted-by":"publisher","unstructured":"Gonzalez-Rodriguez AP, Villa-\u00c1lvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez S (2019) NK cells in the treatment of hematological malignancies. J Clin Med 8(10):1557. https:\/\/doi.org\/10.3390\/jcm8101557","DOI":"10.3390\/jcm8101557"},{"issue":"1","key":"6919_CR47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","volume":"7","author":"T van Hall","year":"2019","unstructured":"van Hall T, Andr\u00e9 P, Horowitz A, Ruan DF, Borst L, Zerbib R et al (2019) Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer 7(1):263","journal-title":"J Immunother Cancer"},{"issue":"10","key":"6919_CR48","doi-asserted-by":"crossref","first-page":"e009934","DOI":"10.1136\/jitc-2024-009934","volume":"12","author":"Y Li","year":"2024","unstructured":"Li Y, Li Z, Tang Y, Zhuang X, Feng W, Boor PP et al (2024) Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J Immunother Cancer 12(10):e009934","journal-title":"J Immunother Cancer"},{"key":"6919_CR49","first-page":"19","volume":"25","author":"S Lee","year":"2024","unstructured":"Lee S, Kim JH, Jang IH, Jo S, Lee SY, Oh SC et al (2024) Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies. Int J Mol Sci 25:19","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6919_CR50","first-page":"e240034","volume":"5","author":"C Gruetzmacher","year":"2025","unstructured":"Gruetzmacher C, Pessoa BS, Craveiro FL, Nakaguma M, Trarbach EB, Batista RL (2025) HHLA2: a potential biomarker and therapeutic target in endocrine-related cancer. Endocr Oncol 5(1):e240034","journal-title":"Endocr Oncol"},{"issue":"2","key":"6919_CR51","doi-asserted-by":"crossref","first-page":"qiae158","DOI":"10.1093\/jleuko\/qiae158","volume":"117","author":"Z Cao","year":"2025","unstructured":"Cao Z, Wang Y, Cheng S-C, He N (2025) Human endogenous retrovirus-H long terminal repeat-associating 2: an emerging immune checkpoint for cancer immunotherapy. J Leukoc Biol 117(2):qiae158","journal-title":"J Leukoc Biol"},{"key":"6919_CR52","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.canlet.2018.11.007","volume":"442","author":"H Yan","year":"2019","unstructured":"Yan H, Qiu W, Koehne de Gonzalez AK, Wei JS, Tu M, Xi CH et al (2019) HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival. Cancer Lett 442:333\u2013340","journal-title":"Cancer Lett"},{"issue":"8","key":"6919_CR53","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/gt.2015.29","volume":"22","author":"MR Wu","year":"2015","unstructured":"Wu MR, Zhang T, DeMars LR, Sentman CL (2015) B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. Gene Ther 22(8):675\u2013684","journal-title":"Gene Ther"},{"key":"6919_CR54","doi-asserted-by":"crossref","first-page":"1378647","DOI":"10.3389\/fonc.2024.1378647","volume":"14","author":"C Jiang","year":"2024","unstructured":"Jiang C, Sun H, Jiang Z, Tian W, Cang S, Yu J (2024) Targeting the CD47\/SIRP\u03b1 pathway in malignancies: recent progress, difficulties and future perspectives. Front Oncol 14:1378647","journal-title":"Front Oncol"},{"issue":"10","key":"6919_CR55","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S (2024) CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 21(10):1089\u20131108","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"6919_CR56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"E Pinto","year":"2025","unstructured":"Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M et al (2025) From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J translational Med 23(1):10","journal-title":"J translational Med"},{"issue":"1","key":"6919_CR57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S et al (2023) Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J translational Med 21(1):449","journal-title":"J translational Med"},{"key":"6919_CR58","first-page":"127","volume-title":"Success and Advancements in the Treatment of Hematological Malignancies","author":"M Hegde","year":"2025","unstructured":"Hegde M, CAR-T-Cell Therapy (2025) Success and Advancements in the Treatment of Hematological Malignancies. Springer, Cell-based Immunotherapies for Cancer, pp 127\u2013159"},{"issue":"2","key":"6919_CR59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12098-023-04635-4","volume":"91","author":"J Sidhu","year":"2024","unstructured":"Sidhu J, Gogoi MP, Krishnan S, Saha V (2024) Relapsed acute lymphoblastic leukemia. Indian J Pediatr 91(2):158\u2013167","journal-title":"Indian J Pediatr"},{"issue":"6","key":"6919_CR60","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1080\/10428194.2021.2020780","volume":"63","author":"KM Sharplin","year":"2022","unstructured":"Sharplin KM, Marks DI (2022) The treatment landscape for relapsed refractory B acute lymphoblastic Leukaemia (ALL). Leuk Lymphoma 63(6):1292\u20131301","journal-title":"Leuk Lymphoma"},{"key":"6919_CR61","unstructured":"Barton C (2025) Engineered T Cell Receptor-T Cell Therapies"},{"key":"6919_CR62","doi-asserted-by":"crossref","first-page":"1149138","DOI":"10.3389\/fphar.2023.1149138","volume":"14","author":"D Hu","year":"2023","unstructured":"Hu D, Chen L, Yan D, Dong W, Chen M, Niu S et al (2023) Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed\/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials. Front Pharmacol 14:1149138","journal-title":"Front Pharmacol"},{"issue":"1","key":"6919_CR63","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X et al (2021) Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Experimental Clin Cancer Res 40(1):367","journal-title":"J Experimental Clin Cancer Res"},{"issue":"1","key":"6919_CR64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13256-024-04905-5","volume":"19","author":"G Menardi","year":"2025","unstructured":"Menardi G, Castellino A, Castellino C, Bersia M, Grande E, Fraternali G et al (2025) Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report. J Med Case Rep 19(1):27","journal-title":"J Med Case Rep"},{"issue":"20","key":"6919_CR65","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN (2023) How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood J Am Soc Hematol 141(20):2430\u20132442","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"6919_CR66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12935-025-03846-3","volume":"25","author":"K Hadiloo","year":"2025","unstructured":"Hadiloo K, Mostanadi P, Asadzadeh A, Taremi S, Esmaeilzadeh A (2025) Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions. Cancer Cell Int 25(1):289","journal-title":"Cancer Cell Int"},{"issue":"1","key":"6919_CR67","first-page":"1","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu Y, Zhao F (2025) Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol Cancer 24(1):1\u201317","journal-title":"Mol Cancer"},{"issue":"6","key":"6919_CR68","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat reviews Clin Oncol 20(6):359\u2013371","journal-title":"Nat reviews Clin Oncol"},{"issue":"19","key":"6919_CR69","doi-asserted-by":"crossref","first-page":"10828","DOI":"10.3390\/ijms221910828","volume":"22","author":"V Pietrobon","year":"2021","unstructured":"Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F (2021) Improving CAR T-cell persistence. Int J Mol Sci 22(19):10828","journal-title":"Int J Mol Sci"},{"key":"6919_CR70","doi-asserted-by":"crossref","unstructured":"van den Bos C, Keefe R, Keville M, McCaman M (2024) Manufacturing and quality of advanced therapeutics: Cellular therapies, CAR-T and gene therapies. Biopharmaceutical manufacturing: Progress, trends and challenges. Springer, pp 453\u2013488","DOI":"10.1007\/978-3-031-45669-5_15"},{"key":"6919_CR71","doi-asserted-by":"crossref","first-page":"780399","DOI":"10.3389\/fimmu.2021.780399","volume":"12","author":"MA Savanur","year":"2021","unstructured":"Savanur MA, Weinstein-Marom H, Gross G (2021) Implementing logic gates for safer immunotherapy of cancer. Front Immunol 12:780399","journal-title":"Front Immunol"},{"issue":"6","key":"6919_CR72","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/JLB.5MR0321-145R","volume":"110","author":"Y Wang","year":"2021","unstructured":"Wang Y, Qiu F, Xu Y, Hou X, Zhang Z, Huang L et al (2021) Stem cell-like memory T cells: the generation and application. J Leukoc Biol 110(6):1209\u20131223","journal-title":"J Leukoc Biol"},{"key":"6919_CR73","doi-asserted-by":"crossref","first-page":"684642","DOI":"10.3389\/fimmu.2021.684642","volume":"12","author":"M Bell","year":"2021","unstructured":"Bell M, Gottschalk S (2021) Engineered cytokine signaling to improve CAR T cell effector function. Front Immunol 12:684642","journal-title":"Front Immunol"},{"key":"6919_CR74","doi-asserted-by":"publisher","unstructured":"P\u00fchl M (2024) Multiple gene editing of T cell inhibitory receptors via CRISPR\/Cas9 in EL4 cells. Dissertation, Charit\u00e9 - Universit\u00e4tsmedizin Berlin. https:\/\/doi.org\/10.17169\/refubium-40645","DOI":"10.17169\/refubium-40645"},{"issue":"6","key":"6919_CR75","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.3390\/ijms23063207","volume":"23","author":"E Ciraolo","year":"2022","unstructured":"Ciraolo E, Althoff S, Ru\u00df J, Rosnev S, Butze M, P\u00fchl M et al (2022) Simultaneous genetic ablation of PD-1, LAG-3, and TIM-3 in CD8 T cells delays tumor growth and improves survival outcome. Int J Mol Sci 23(6):3207","journal-title":"Int J Mol Sci"},{"issue":"82","key":"6919_CR76","doi-asserted-by":"crossref","first-page":"eabq3016","DOI":"10.1126\/sciimmunol.abq3016","volume":"8","author":"J-J Peng","year":"2023","unstructured":"Peng J-J, Wang L, Li Z, Ku C-L, Ho P-C (2023) Metabolic challenges and interventions in CAR T cell therapy. Sci Immunol 8(82):eabq3016","journal-title":"Sci Immunol"},{"issue":"6","key":"6919_CR77","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s11095-021-03067-z","volume":"38","author":"M Sadeqi Nezhad","year":"2021","unstructured":"Sadeqi Nezhad M, Abdollahpour-Alitappeh M, Rezaei B, Yazdanifar M, Seifalian AM (2021) Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products. Pharm Res 38(6):931\u2013945","journal-title":"Pharm Res"},{"issue":"4","key":"6919_CR78","doi-asserted-by":"crossref","first-page":"e13425","DOI":"10.1111\/cpr.13425","volume":"56","author":"C Wang","year":"2023","unstructured":"Wang C, Liu J, Li W (2023) Off the shelf\u2019immunotherapies: Generation and application of pluripotent stem cell-derived immune cells. Cell Prolif 56(4):e13425","journal-title":"Cell Prolif"},{"key":"6919_CR79","doi-asserted-by":"crossref","unstructured":"Jamwal R (2024) 3 Gene Therapy Utilizing. Nanoparticles in Cancer Therapy: Innovations and Clinical Applications. :31","DOI":"10.1201\/9781003515630-4"},{"key":"6919_CR80","doi-asserted-by":"publisher","unstructured":"Marin ND, Zhou A, Jacobs MT, Fehniger TA (2024) \"Off the shelf\" CAR-T\/NK cells. In: O'Connor OA, Ansell SM, Gribben JG (eds) Precision cancer therapies, volume 2: immunologic approaches for the treatment of lymphoid malignancies: from concept to practice. Wiley, Hoboken, pp 341\u2013359. https:\/\/doi.org\/10.1002\/9781119824572.ch23","DOI":"10.1002\/9781119824572.ch23"},{"key":"6919_CR81","doi-asserted-by":"publisher","unstructured":"Rajalingam R (2025) Harnessing natural killer cells for cancer therapy. In: Shoenfeld Y, Meroni P, Gershwin ME (eds) Handbook of cancer and immunology. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-030-80962-1_319-1","DOI":"10.1007\/978-3-030-80962-1_319-1"},{"issue":"1","key":"6919_CR82","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","volume":"14","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob MB, Barington T (2025) The clinical landscape of CAR NK cells. Experimental Hematol Oncol 14(1):46","journal-title":"Experimental Hematol Oncol"},{"issue":"4","key":"6919_CR83","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/cancers14040978","volume":"14","author":"LG White","year":"2022","unstructured":"White LG, Goy HE, Rose AJ, McLellan AD (2022) Controlling cell trafficking: addressing failures in CAR T and NK cell therapy of solid tumours. Cancers 14(4):978","journal-title":"Cancers"},{"key":"6919_CR84","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","volume":"27","author":"X Wu","year":"2022","unstructured":"Wu X, Matosevic S (2022) Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy. Mol Therapy-Oncolytics 27:224\u2013238","journal-title":"Mol Therapy-Oncolytics"},{"key":"6919_CR85","doi-asserted-by":"publisher","unstructured":"Aramini B, Masciale V, Grisendi G, Bertolini F, Maur M, Guaitoli G, Dominici M, Haider KH (2022) Dissecting tumor growth: the role of cancer stem cells in drug resistance and recurrence. Cancers (Basel) 14(4):976. https:\/\/doi.org\/10.3390\/cancers14040976","DOI":"10.3390\/cancers14040976"},{"key":"6919_CR86","doi-asserted-by":"publisher","unstructured":"Doherty MR, Smigiel JM, Junk DJ, Jackson MW (2016) Cancer stem cell plasticity drives therapeutic resistance. Cancers (Basel) 8(1):8. https:\/\/doi.org\/10.3390\/cancers8010008","DOI":"10.3390\/cancers8010008"},{"issue":"1","key":"6919_CR87","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","volume":"43","author":"GR Bhat","year":"2024","unstructured":"Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N et al (2024) Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev 43(1):197\u2013228","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"6919_CR88","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.trecan.2022.04.007","volume":"8","author":"SR Torborg","year":"2022","unstructured":"Torborg SR, Li Z, Chan JE, Tammela T (2022) Cellular and molecular mechanisms of plasticity in cancer. Trends Cancer 8(9):735\u2013746","journal-title":"Trends Cancer"},{"issue":"16","key":"6919_CR89","doi-asserted-by":"crossref","first-page":"eadt7682","DOI":"10.1126\/sciadv.adt7682","volume":"11","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Zhang L, Xia L, Wang EH, Lu T (2025) A METTL3-NFE2L3 axis mediates tumor stemness and progression in lung adenocarcinoma. Sci Adv 11(16):eadt7682","journal-title":"Sci Adv"},{"issue":"2","key":"6919_CR90","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2159-8290.CD-20-0331","volume":"11","author":"D Dixit","year":"2021","unstructured":"Dixit D, Prager BC, Gimple RC, Poh HX, Wang Y, Wu Q et al (2021) The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov 11(2):480\u2013499","journal-title":"Cancer Discov"},{"issue":"7","key":"6919_CR91","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4252\/wjsc.v11.i7.398","volume":"11","author":"FY Du","year":"2019","unstructured":"Du FY, Zhou QF, Sun WJ, Chen GL (2019) Targeting cancer stem cells in drug discovery: Current state and future perspectives. World J Stem Cells 11(7):398\u2013420","journal-title":"World J Stem Cells"},{"key":"6919_CR92","doi-asserted-by":"publisher","unstructured":"Rinkenbaugh AL, Baldwin AS (2016) The NF-\u03baB pathway and cancer stem cells. Cells 5(2):16. https:\/\/doi.org\/10.3390\/cells5020016","DOI":"10.3390\/cells5020016"},{"issue":"3","key":"6919_CR93","doi-asserted-by":"crossref","first-page":"e105977","DOI":"10.15252\/embj.2020105977","volume":"40","author":"PC He","year":"2021","unstructured":"He PC, He C (2021) m6A RNA methylation: from mechanisms to therapeutic potential. EMBO J 40(3):e105977","journal-title":"EMBO J"},{"key":"6919_CR94","doi-asserted-by":"crossref","first-page":"1465222","DOI":"10.3389\/fddsv.2024.1465222","volume":"4","author":"H Zhang","year":"2024","unstructured":"Zhang H, Wang X, Chen J, Su R (2024) Combating cancer stem cells: RNA m6A methylation and small-molecule drug discovery. Front Drug Discovery 4:1465222","journal-title":"Front Drug Discovery"},{"key":"6919_CR95","doi-asserted-by":"crossref","first-page":"1629864","DOI":"10.3389\/fonc.2025.1629864","volume":"15","author":"X Liu","year":"2025","unstructured":"Liu X, Kan X (2025) Small-molecule and peptide inhibitors of m6A regulators. Front Oncol 15:1629864","journal-title":"Front Oncol"},{"issue":"4","key":"6919_CR96","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/oncsis.2017.14","volume":"6","author":"S-G Pohl","year":"2017","unstructured":"Pohl S-G, Brook N, Agostino M, Arfuso F, Kumar AP, Dharmarajan A (2017) Wnt signaling in triple-negative breast cancer. Oncogenesis 6(4):e310\u2013e","journal-title":"Oncogenesis"},{"issue":"7768","key":"6919_CR97","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H et al (2019) Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572(7768):254\u2013259","journal-title":"Nature"},{"issue":"21","key":"6919_CR98","doi-asserted-by":"crossref","first-page":"e103479","DOI":"10.15252\/embj.2019103479","volume":"38","author":"B Heyman","year":"2019","unstructured":"Heyman B, Jamieson C (2019) To PARP or not to PARP?-Toward sensitizing acute myeloid leukemia stem cells to immunotherapy. Embo j 38(21):e103479","journal-title":"Embo j"},{"issue":"6","key":"6919_CR99","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41594-021-00606-5","volume":"28","author":"J Li","year":"2021","unstructured":"Li J, Gregory RI (2021) Mining for METTL3 inhibitors to suppress cancer. Nat Struct Mol Biol 28(6):460\u2013462","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"6919_CR100","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/jacsau.4c00754","volume":"5","author":"X Qiu","year":"2025","unstructured":"Qiu X, Kemker C, Goebel GL, Lampe P, Wallis N, Schiller D et al (2025) Phenylpyrazoles as Inhibitors of the m(6)A RNA-Binding Protein YTHDF2. JACS Au 5(2):618\u2013630","journal-title":"JACS Au"},{"key":"6919_CR101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtn.2020.10.031","volume":"23","author":"H Yu","year":"2021","unstructured":"Yu H, Yang X, Tang J, Si S, Zhou Z, Lu J et al (2021) ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2\u03b1-Mediated Glycolysis. Mol Ther Nucleic Acids 23:27\u201341","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"6919_CR102","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tcb.2014.11.006","volume":"25","author":"F Klemm","year":"2015","unstructured":"Klemm F, Joyce JA (2015) Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 25(4):198\u2013213","journal-title":"Trends Cell Biol"},{"issue":"4","key":"6919_CR103","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s13402-024-00931-z","volume":"47","author":"D Coursier","year":"2024","unstructured":"Coursier D, Calvo F (2024) CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance. Cell Oncol 47(4):1091\u20131112","journal-title":"Cell Oncol"},{"issue":"1","key":"6919_CR104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11658-020-00246-5","volume":"26","author":"W Liang","year":"2021","unstructured":"Liang W, Chen X, Zhang S, Fang J, Chen M, Xu Y et al (2021) Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines. Cell Mol Biol Lett 26(1):3","journal-title":"Cell Mol Biol Lett"},{"issue":"2","key":"6919_CR105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers13020210","volume":"13","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M (2021) The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers 13(2):210","journal-title":"Cancers"},{"issue":"1","key":"6919_CR106","first-page":"109","volume":"13","author":"L Li","year":"2013","unstructured":"Li L, Cole J, Margolin DA (2013) Cancer stem cell and stromal microenvironment. Ochsner J 13(1):109\u2013118","journal-title":"Ochsner J"},{"issue":"4","key":"6919_CR107","first-page":"1","volume":"67","author":"Y Wang","year":"2025","unstructured":"Wang Y, Luo S, Dong H, Huang R-P (2025) Unraveling tumor cell\u2013tumor microenvironment crosstalk through antibody array technologies. Int J Oncol 67(4):1\u201314","journal-title":"Int J Oncol"},{"issue":"15","key":"6919_CR108","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3390\/cancers17152484","volume":"17","author":"JS Pawar","year":"2025","unstructured":"Pawar JS, Salam MA, Dipto MSU, Al-Amin MY, Salam MT, Sengupta S et al (2025) Cancer-Associated Fibroblasts: Immunosuppressive Crosstalk with Tumor-Infiltrating Immune Cells and Implications for Therapeutic Resistance. Cancers 17(15):2484","journal-title":"Cancers"},{"key":"6919_CR109","doi-asserted-by":"crossref","first-page":"908389","DOI":"10.3389\/fcell.2022.908389","volume":"10","author":"V Melo","year":"2022","unstructured":"Melo V, Bremer E, Martin JD (2022) Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment. Front Cell Dev Biol 10:908389","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"6919_CR110","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A et al (2025) The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat Cancer 6(6):924\u2013937","journal-title":"Nat Cancer"},{"issue":"6","key":"6919_CR111","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1007\/s13346-021-01018-0","volume":"11","author":"S Aghlara-Fotovat","year":"2021","unstructured":"Aghlara-Fotovat S, Nash A, Kim B, Krencik R, Veiseh O (2021) Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies. Drug delivery translational Res 11(6):2394\u20132413","journal-title":"Drug delivery translational Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06919-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06919-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06919-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:20Z","timestamp":1776405560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06919-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":111,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6919"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06919-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}}],"article-number":"215"}}